Junshi Bio's stock surged 5.06% during intraday trading on Tuesday, reflecting positive investor sentiment following significant corporate developments.

The company's board of directors approved a new 2026 A-Share Employee Stock Ownership Plan (ESOP), which aims to enhance alignment between employees and shareholders, strengthen workforce cohesion, and support long-term corporate development. The ESOP requires shareholder approval at the forthcoming general meeting to become effective.

Additionally, the board reviewed and approved the company's first-quarter 2026 report, which showed operating income of RMB726.3 million alongside a net loss attributable of RMB20.6 million. All resolutions were passed unanimously by the 14 attending directors, underscoring the company's focus on governance transparency and strategic talent incentives.